You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTorasemide
Accession NumberDB00214  (APRD00217, APRD00295)
TypeSmall Molecule
GroupsApproved
Description

Torasemide (rINN) or torsemide (USAN) is a pyridine-sulfonylurea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. [Wikipedia]

Structure
Thumb
Synonyms
1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
Demadex
Luprac
N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
Torasemida
Torasemidum
Torsemide
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Demadextablet5 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet20 mg/1oralPhysicians Total Care, Inc.2009-10-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet10 mg/1oralPhysicians Total Care, Inc.2000-11-28Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet20 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet10 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet5 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet100 mg/1oralMeda Pharmaceuticals Inc.2009-02-202016-01-20Us 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet20 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet10 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadextablet100 mg/1oralMEDA Pharmaceuticals2015-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Demadex Injection - 10mg/mlliquid10 mgintravenousHoffmann La Roche Limited1995-12-312000-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Demadex Tablets - 100mgtablet100 mgoralHoffmann La Roche Limited1995-12-312000-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Demadex Tablets - 10mgtablet10 mgoralHoffmann La Roche Limited1995-12-312000-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Demadex Tablets - 20mgtablet20 mgoralHoffmann La Roche Limited1996-12-312000-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Demadex Tablets - 5mgtablet5 mgoralHoffmann La Roche Limited1995-12-312000-07-27Canada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Torsemidetablet5 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralPliva, Inc2004-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralRoxane Laboratories, Inc2005-03-03Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralAv Pak2014-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-07-19Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralApotex Corp.2005-06-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralCardinal Health2010-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralAv Pak2014-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralApotex Corp.2005-06-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralCardinal Health2010-01-14Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralbryant ranch prepack2009-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralAv Pak2014-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralApotex Corp.2005-06-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralPhysicians Total Care, Inc.2009-06-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralAv Kare, Inc.2014-12-29Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralbryant ranch prepack2011-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralAv Pak2014-10-07Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralApotex Corp.2005-06-06Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralPhysicians Total Care, Inc.2005-04-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralPliva, Inc2004-10-20Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralQualitest Pharmaceuticals2011-03-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralCarilion Materials Management2011-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralPhysicians Total Care, Inc.2012-08-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralPliva, Inc2004-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemideinjection, solution10 mg/mLintravenousAmerican Regent, Inc.2010-05-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralCarilion Materials Management2011-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemideinjection10 mg/mLintravenousGENERAL INJECTABLES AND VACCINES, INC.2010-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralCardinal Health2004-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet100 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralCitron Pharma LLC2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralPliva, Inc2004-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemideinjection, solution10 mg/mLintravenousAmerican Regent, Inc.2010-05-21Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralAmerican Health Packaging2013-07-22Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemideinjection10 mg/mLintravenousGENERAL INJECTABLES AND VACCINES, INC.2010-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralCamber Pharmaceuticals, Inc.2011-01-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet5 mg/1oralSun Pharmaceutical Industries Limited2008-02-26Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralCardinal Health2004-06-01Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet20 mg/1oralPar Pharmaceutical Inc2009-01-27Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Torsemidetablet10 mg/1oralAurobindo Pharma Limited2007-10-17Not applicableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Over the Counter ProductsNot Available
International Brands
NameCompany
DiuverNot Available
ExamideNot Available
LupracNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIW31X2H97FB
CAS number56211-40-6
WeightAverage: 348.42
Monoisotopic: 348.125611216
Chemical FormulaC16H20N4O3S
InChI KeyInChIKey=NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)
IUPAC Name
1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea
SMILES
CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassPyridinesulfonamides
Direct ParentPyridinesulfonamides
Alternative Parents
Substituents
  • Pyridine-3-sulfonamide
  • Aminotoluene
  • Substituted aniline
  • Toluene
  • Sulfonylurea
  • Aniline
  • Aminopyridine
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.
PharmacodynamicsTorasemide (INN) or torsemide (USAN) is a novel loop diuretic belonging to pridine sulphonyl urea. It differs form other thiazide diuretics in that a double ring system is incorporated into its structure. Like thiazides, loop diuretics must be secreted into the tubular fluid by proximal tubule cells. In the thick ascending loop Na+ and Cl- reabsorption is accomplished by a Na+/K+/2Cl- symporter. The thick ascending limb has a high reabsorptive capacity and is responsible for reabsorbing 25% of the filtered load of Na+. The loop diuretics act by blocking this symporter. Because of the large absorptive capacity and the amount of Na+ delivered to the ascending limb, loop diuretics have a profound diuretic action. In addition, more distal nephron segments do not have the reabsorptive capacity to compensate for this increased load. The osmotic gradient for water reabsorption is also reduced resulting in an increase in the amount of water excreted.
Mechanism of actionTorasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and By increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.
AbsorptionRapidly absorbed following oral administration. Absolute bioavailability is 80%. Food has no effect on absorption.
Volume of distribution
  • 12 to 15 L [normal adults or in patients with mild to moderate renal failure or congestive heart failure]
Protein binding> 99%
Metabolism

Metabolized via the hepatic CYP2C8 to 5 metabolites. The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.

SubstrateEnzymesProduct
Torasemide
hydroxytorsemideDetails
Route of eliminationTorsemide is cleared from the circulation by both hepatic metabolism (approximately 80% of total clearance) and excretion into the urine (approximately 20% of total clearance in patients with normal renal function).
Half life3.5 hours
ClearanceNot Available
ToxicitySymptoms of overdose include dehydration, hypovolemia, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, and hemoconcentration. Oral LD50 in rat is 5 g/kg, and intravenous LD50 in rat is 500 mg/kg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.6871
Caco-2 permeable-0.5374
P-glycoprotein substrateNon-substrate0.799
P-glycoprotein inhibitor INon-inhibitor0.7695
P-glycoprotein inhibitor IINon-inhibitor0.8232
Renal organic cation transporterNon-inhibitor0.9185
CYP450 2C9 substrateSubstrate0.6049
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7558
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.6692
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.5905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6324
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8366
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8740 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9854
hERG inhibition (predictor II)Non-inhibitor0.8668
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Bedford laboratories
  • Luitpold pharmaceuticals inc
  • Meda pharmaceuticals inc
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Hetero drugs ltd
  • Par pharmaceutical inc
  • Pliva pharmaceutical industry inc
  • Roxane laboratories inc
  • Sun pharmaceutical industries ltd
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg/1
Tabletoral100 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Liquidintravenous10 mg
Tabletoral100 mg
Tabletoral10 mg
Tabletoral20 mg
Tabletoral5 mg
Injectionintravenous10 mg/mL
Injection, solutionintravenous10 mg/mL
Prices
Unit descriptionCostUnit
Demadex 100 mg tablet5.69USD tablet
Torsemide 100 mg tablet3.16USD tablet
Demadex 20 mg tablet1.59USD tablet
Demadex 10 mg tablet1.39USD tablet
Demadex 5 mg tablet1.28USD tablet
Torsemide 20 mg tablet0.85USD tablet
Torsemide 10 mg tablet0.73USD tablet
Torsemide 5 mg tablet0.66USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point164-164 °CNot Available
water solubilityWater solubleNot Available
logP2.3Not Available
pKa7.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0596 mg/mLALOGPS
logP1.76ALOGPS
logP1.86ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)5.92ChemAxon
pKa (Strongest Basic)4.2ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area100.19 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity91.89 m3·mol-1ChemAxon
Polarizability36.15 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Fritz Topfmeier, Gustav Lettenbauer, “Process for the preparation of a stable modification of torasemide.” U.S. Patent USRE0345806, issued June, 1975.

USRE0345806
General References
  1. Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. Pubmed
  2. FDA approved new drug bulletin: torsemide (Demadex), trimetrexate glucuronate (neuTrexin). RN. 1994 May;57(5):53-6. Pubmed
External Links
ATC CodesC03CA04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (110 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Torasemide can be increased when it is combined with Abiraterone.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Torasemide.
Acetylsalicylic acidAcetylsalicylic acid may decrease the diuretic activities of Torasemide.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Torasemide.
AllopurinolThe risk or severity of adverse effects can be increased when Torasemide is combined with Allopurinol.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.
AmifostineTorasemide may increase the hypotensive activities of Amifostine.
AmikacinThe risk or severity of adverse effects can be increased when Torasemide is combined with Amikacin.
Aminosalicylic AcidAminosalicylic Acid may decrease the diuretic activities of Torasemide.
ArbekacinThe risk or severity of adverse effects can be increased when Torasemide is combined with Arbekacin.
ArformoterolArformoterol may increase the hypokalemic activities of Torasemide.
Atracurium besylateTorasemide may decrease the neuromuscular blocking activities of Atracurium besylate.
BenazeprilTorasemide may increase the hypotensive activities of Benazepril.
BetamethasoneBetamethasone may increase the hypokalemic activities of Torasemide.
Bismuth SubsalicylateBismuth Subsalicylate may decrease the diuretic activities of Torasemide.
BrimonidineBrimonidine may increase the antihypertensive activities of Torasemide.
BudesonideBudesonide may increase the hypokalemic activities of Torasemide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Torasemide.
ButabarbitalButabarbital may increase the hypotensive activities of Torasemide.
ButethalButethal may increase the hypotensive activities of Torasemide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Torasemide.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Torasemide.
CanagliflozinCanagliflozin may increase the hypotensive activities of Torasemide.
CaptoprilTorasemide may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Torasemide can be increased when combined with Carbamazepine.
CelecoxibThe metabolism of Torasemide can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Torasemide can be increased when it is combined with Ceritinib.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Torasemide.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Torasemide.
CholestyramineCholestyramine can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilTorasemide may increase the hypotensive activities of Cilazapril.
Cisatracurium besylateTorasemide may decrease the neuromuscular blocking activities of Cisatracurium besylate.
CisplatinTorasemide may increase the nephrotoxic activities of Cisplatin.
ClopidogrelThe metabolism of Torasemide can be decreased when combined with Clopidogrel.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Torasemide.
ColesevelamColesevelam can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Torasemide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CorticotropinCorticotropin may increase the hypokalemic activities of Torasemide.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Torasemide.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Torasemide.
DabrafenibThe serum concentration of Torasemide can be decreased when it is combined with Dabrafenib.
DeferasiroxThe serum concentration of Torasemide can be increased when it is combined with Deferasirox.
DexamethasoneDexamethasone may increase the hypokalemic activities of Torasemide.
DiazoxideDiazoxide may increase the hypotensive activities of Torasemide.
DiclofenacDiclofenac may decrease the diuretic activities of Torasemide.
DiflunisalDiflunisal may decrease the diuretic activities of Torasemide.
DigoxinThe risk or severity of adverse effects can be increased when Torasemide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Torasemide.
DofetilideTorasemide may increase the QTc-prolonging activities of Dofetilide.
DuloxetineTorasemide may increase the orthostatic hypotensive activities of Duloxetine.
EfavirenzThe metabolism of Torasemide can be decreased when combined with Efavirenz.
EltrombopagThe serum concentration of Torasemide can be increased when it is combined with Eltrombopag.
EnalaprilTorasemide may increase the hypotensive activities of Enalapril.
EnalaprilatTorasemide may increase the hypotensive activities of Enalaprilat.
EtodolacEtodolac may decrease the diuretic activities of Torasemide.
FelodipineThe metabolism of Torasemide can be decreased when combined with Felodipine.
FenoprofenFenoprofen may decrease the diuretic activities of Torasemide.
FenoterolFenoterol may increase the hypokalemic activities of Torasemide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Torasemide.
FloctafenineFloctafenine may decrease the diuretic activities of Torasemide.
FloxuridineThe metabolism of Torasemide can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Torasemide can be decreased when combined with Fluconazole.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Torasemide.
FlunisolideFlunisolide may increase the hypokalemic activities of Torasemide.
FlurbiprofenFlurbiprofen may decrease the diuretic activities of Torasemide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Torasemide.
FormoterolFormoterol may increase the hypokalemic activities of Torasemide.
FoscarnetThe serum concentration of Foscarnet can be increased when it is combined with Torasemide.
FosinoprilTorasemide may increase the hypotensive activities of Fosinopril.
FosphenytoinFosphenytoin may decrease the diuretic activities of Torasemide.
FramycetinThe risk or severity of adverse effects can be increased when Torasemide is combined with Framycetin.
GemfibrozilThe metabolism of Torasemide can be decreased when combined with Gemfibrozil.
GentamicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Gentamicin.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Torasemide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Torasemide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Torasemide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Torasemide.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Torasemide.
HexobarbitalHexobarbital may increase the hypotensive activities of Torasemide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Torasemide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Torasemide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Torasemide.
IbuprofenIbuprofen may decrease the diuretic activities of Torasemide.
IndacaterolIndacaterol may increase the hypokalemic activities of Torasemide.
IndomethacinIndomethacin may decrease the diuretic activities of Torasemide.
InfliximabInfliximab may decrease the diuretic activities of Torasemide.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Torasemide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Torasemide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Torasemide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Torasemide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Torasemide.
Insulin RegularThe therapeutic efficacy of Insulin Regular can be decreased when used in combination with Torasemide.
Insulin, isophaneThe therapeutic efficacy of Insulin, isophane can be decreased when used in combination with Torasemide.
Ipratropium bromideIpratropium bromide may increase the hypokalemic activities of Torasemide.
IrbesartanThe metabolism of Torasemide can be decreased when combined with Irbesartan.
IvabradineTorasemide may increase the arrhythmogenic activities of Ivabradine.
KanamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Kanamycin.
KetoprofenKetoprofen may decrease the diuretic activities of Torasemide.
KetorolacKetorolac may decrease the diuretic activities of Torasemide.
LapatinibThe metabolism of Torasemide can be decreased when combined with Lapatinib.
LevodopaTorasemide may increase the orthostatic hypotensive activities of Levodopa.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Torasemide.
LicoriceLicorice may increase the hypokalemic activities of Torasemide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Torasemide.
LisinoprilTorasemide may increase the hypotensive activities of Lisinopril.
LithiumThe serum concentration of Lithium can be decreased when it is combined with Torasemide.
LopinavirThe metabolism of Torasemide can be decreased when combined with Lopinavir.
LosartanThe metabolism of Torasemide can be decreased when combined with Losartan.
LumacaftorThe serum concentration of Torasemide can be decreased when it is combined with Lumacaftor.
Magnesium salicylateMagnesium salicylate may decrease the diuretic activities of Torasemide.
MecamylamineThe risk or severity of adverse effects can be increased when Torasemide is combined with Mecamylamine.
Mefenamic acidMefenamic acid may decrease the diuretic activities of Torasemide.
MeloxicamMeloxicam may decrease the diuretic activities of Torasemide.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Torasemide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.
MethohexitalMethohexital may increase the hypotensive activities of Torasemide.
MethotrexateThe therapeutic efficacy of Torasemide can be decreased when used in combination with Methotrexate.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Torasemide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Torasemide.
MifepristoneThe serum concentration of Torasemide can be increased when it is combined with Mifepristone.
MoexiprilTorasemide may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Torasemide.
MometasoneMometasone may increase the hypokalemic activities of Torasemide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Torasemide.
MoxonidineMoxonidine may increase the hypotensive activities of Torasemide.
NabumetoneNabumetone may decrease the diuretic activities of Torasemide.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Torasemide.
NaproxenNaproxen may decrease the diuretic activities of Torasemide.
NeomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Neomycin.
NetilmicinThe risk or severity of adverse effects can be increased when Torasemide is combined with Netilmicin.
NicorandilNicorandil may increase the hypotensive activities of Torasemide.
NilotinibThe metabolism of Torasemide can be decreased when combined with Nilotinib.
ObinutuzumabTorasemide may increase the hypotensive activities of Obinutuzumab.
OlodaterolOlodaterol may increase the hypokalemic activities of Torasemide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Torasemide.
OxaprozinOxaprozin may decrease the diuretic activities of Torasemide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Torasemide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Torasemide.
PancuroniumTorasemide may decrease the neuromuscular blocking activities of Pancuronium.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Torasemide.
PentobarbitalPentobarbital may increase the hypotensive activities of Torasemide.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Torasemide.
PerindoprilTorasemide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Torasemide.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Torasemide.
PhenobarbitalThe metabolism of Torasemide can be increased when combined with Phenobarbital.
PhenytoinPhenytoin may decrease the diuretic activities of Torasemide.
PioglitazoneThe metabolism of Torasemide can be decreased when combined with Pioglitazone.
PirbuterolPirbuterol may increase the hypokalemic activities of Torasemide.
PiroxicamPiroxicam may decrease the diuretic activities of Torasemide.
PrednisolonePrednisolone may increase the hypokalemic activities of Torasemide.
PrednisonePrednisone may increase the hypokalemic activities of Torasemide.
PrimidonePrimidone may increase the hypotensive activities of Torasemide.
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Torasemide.
QuinaprilTorasemide may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Torasemide.
RabeprazoleThe metabolism of Torasemide can be decreased when combined with Rabeprazole.
RamiprilTorasemide may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Torasemide.
Repository corticotropinRepository corticotropin may increase the hypokalemic activities of Torasemide.
RibostamycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Ribostamycin.
RifampicinThe metabolism of Torasemide can be increased when combined with Rifampicin.
RifapentineThe metabolism of Torasemide can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Torasemide is combined with Risperidone.
RitonavirThe metabolism of Torasemide can be decreased when combined with Ritonavir.
RituximabTorasemide may increase the hypotensive activities of Rituximab.
RocuroniumTorasemide may decrease the neuromuscular blocking activities of Rocuronium.
RosiglitazoneThe metabolism of Torasemide can be decreased when combined with Rosiglitazone.
SalbutamolSalbutamol may increase the hypokalemic activities of Torasemide.
Salicylate-sodiumSalicylate-sodium may decrease the diuretic activities of Torasemide.
SalmeterolSalmeterol may increase the hypokalemic activities of Torasemide.
SalsalateSalsalate may decrease the diuretic activities of Torasemide.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Torasemide.
SecobarbitalSecobarbital may increase the hypotensive activities of Torasemide.
SpectinomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Spectinomycin.
StiripentolThe metabolism of Torasemide can be decreased when combined with Stiripentol.
StreptomycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Streptomycin.
SuccinylcholineTorasemide may decrease the neuromuscular blocking activities of Succinylcholine.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.
SulfamethoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleThe metabolism of Torasemide can be decreased when combined with Sulfisoxazole.
SulindacSulindac may decrease the diuretic activities of Torasemide.
SulpirideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sulpiride.
TadalafilTadalafil may increase the antihypertensive activities of Torasemide.
TamoxifenThe metabolism of Torasemide can be decreased when combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Torasemide.
TerbutalineTerbutaline may increase the hypokalemic activities of Torasemide.
TeriflunomideThe serum concentration of Torasemide can be increased when it is combined with Teriflunomide.
Tiaprofenic acidTiaprofenic acid may decrease the diuretic activities of Torasemide.
TobramycinThe risk or severity of adverse effects can be increased when Torasemide is combined with Tobramycin.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Torasemide.
TolmetinTolmetin may decrease the diuretic activities of Torasemide.
TopiramateTorasemide may increase the hypokalemic activities of Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide.
TrandolaprilTorasemide may increase the hypotensive activities of Trandolapril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Torasemide.
TreprostinilTreprostinil may increase the hypotensive activities of Torasemide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Torasemide.
TrimethoprimThe metabolism of Torasemide can be decreased when combined with Trimethoprim.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide.
VardenafilVardenafil may increase the antihypertensive activities of Torasemide.
VecuroniumTorasemide may decrease the neuromuscular blocking activities of Vecuronium.
VilanterolVilanterol may increase the hypokalemic activities of Torasemide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Torasemide.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Torasemide.
YohimbineYohimbine may decrease the antihypertensive activities of Torasemide.
Food InteractionsNot Available

Targets

1. Solute carrier family 12 member 1

Kind: Protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 12 member 1 Q13621 Details

References:

  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
  2. Vormfelde SV, Sehrt D, Toliat MR, Schirmer M, Meineke I, Tzvetkov M, Nurnberg P, Brockmoller J: Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. Epub 2007 Apr 25. Pubmed
  3. Fortuno A, Muniz P, Ravassa S, Rodriguez JA, Fortuno MA, Zalba G, Diez J: Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension. 1999 Jul;34(1):138-43. Pubmed

Enzymes

1. Cytochrome P450 2C8

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 2C9

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Prostaglandin G/H synthase 1

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Prostaglandin G/H synthase 1 P23219 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed

4. Cytochrome P450 2C19

Kind: Protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 25, 2013 12:39